Fredun Medhora has built a ₹500 crore revenue pharmaceuticals-to-consumer company, compounding at 30% CAGR over 17 years. He believes his company has finally arrived at its inflection point.
The Fredun Story
Fredun Medhora has built a ₹500 crore revenue pharmaceuticals-to-consumer company, compounding at 30% CAGR over 17 years. He believes his company has finally arrived at its inflection point.